Antibody–Drug Conjugates: A Novel Paradigm for Cancer Therapy
Chemotherapy is one of the most widely used treatment approaches for cancer. However, it can often cause serious side effects, posing challenges for drug developers.
Antibody–drug conjugates (ADCs) combine the effective killing power of small molecule cytotoxins and the highly specific targeting ability of monoclonal antibodies, and so can precisely deliver cytotoxins to tumor cells, while minimally affecting normal cells.
This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.
Download this whitepaper to learn more about:
- Currently approved ADCs and their indications
- The mechanism of action of ADC drugs
- Overcoming cytotoxic payload challenges in drug development